Gastroenterology
-
Comparative Study
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
To elucidate the survival of the patients with unresectable hepatocellular carcinoma (HCC) who underwent transcatheter arterial lipiodol chemoembolization (TACE) and to analyze the factors affecting the survivals. ⋯ TACE showed safe therapeutic modality with a 5-year survival of 26% for unresectable HCC patients. The degrees of liver damage, TNM stage, and alpha-fetoprotein values were independent risk factors for patient survival.